title: CD8+CD38+ and CD8+DR+ peripheral blood lymphoid subsets of HIV-infected intravenous drug abusers correlate with CD4+ cell counts and proliferation to mitogens.
abstract: Twenty-nine intravenous drug abusers (ivda), with asymptomatic HIV infection at entry, were sequentially studied at 4- to 6-month intervals for variable follow-up periods (mean, 19.6 months). Two of them progressed to AIDS and another one fell into the IV-C2 stage of the CDC classification at the end of the study. CD8+ lymphoid subsets (CD57+, CD38+, and HLA-DR+) were sequentially analyzed in peripheral blood samples along the follow-up. Both absolute number and percentage of cells within these subsets were found significantly increased over those observed in normal controls. Minor changes were appreciated throughout the follow-up. CD8+CD38+ and CD8+DR+ cells increased slightly (P < 0.05), but the CD8+CD57+ subset did not change significantly. In order to determine whether abnormalities in these subsets are associated with immune dysfunction, we looked for correlation between the quantification of CD8+ subpopulations and other parameters of cellular immunity. Percentage of CD8+CD38+ or CD8+DR+ cells inversely correlates with absolute number of CD4+ cells (P < 0.0001), and percentage of CD38+ subset also correlates with the proliferative response to mitogens in lymphoid cultures. Thus, the enumeration of these populations of CD8+ cells may provide some additional information about the immune status of HIV-infected ivda.
authors.affiliation: Servicios de Inmunología, Hospital Nuestra Señora de Aránzazu, San Sebastián, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Echaniz
authors.forename: J
authors.initials: J
authors.lastname: Arrizabalaga
authors.forename: J A
authors.initials: JA
authors.lastname: Iribarren
authors.forename: E
authors.initials: E
authors.lastname: Cuadrado
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D015703:Antigens, CD / Q000032:analysis; D000943:Antigens, Differentiation / Q000032:analysis*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018959:CD57 Antigens; D016827:CD8 Antigens / Q000032:analysis*; D015658:HIV Infections / Q000276:immunology*; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins; D012044:Regression Analysis; D015819:Substance Abuse, Intravenous / Q000276:immunology*; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013997:Time Factors
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; D000945:Antigens, Differentiation, T-Lymphocyte; D018959:CD57 Antigens; D016827:CD8 Antigens; D006684:HLA-DR Antigens; D008562:Membrane Glycoproteins; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1